HII (NYSE:HII) has secured a $336 million contract from the U.S. Navy for the procurement of long-lead time materials for the upcoming aircraft carrier CVN 82. This undefinitized contract will specifically fund the advanced procurement of propulsion plant materials for the vessel's future construction at HII’s Newport News Shipbuilding division. The agreement highlights the initial phase of planning for the nuclear-powered aircraft carrier and supports thousands of suppliers within the industrial base.

Employees at a Starbucks location in downtown Hamilton, Ontario, have successfully unionized with the United Steelworkers (USW), becoming the latest Canadian Starbucks store to do so. The workers raised concerns including health and safety, unclear time and attendance policies, lack of seniority recognition, and the impact of corporate changes on wages and benefits. The USW will now help these employees elect a bargaining committee and negotiate their first collective agreement.

Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals (NASDAQ: REGN) on behalf of investors who suffered substantial losses due to alleged misleading statements regarding a Phase 3 clinical trial for a melanoma therapy. The lawsuit claims Regeneron made false statements and failed to disclose critical information about the trial's flawed statistical assumptions and the unlikelihood of achieving its primary endpoint. The deadline for investors to lead the class action lawsuit is September 14, 2026.

Elevance Health (ELV) has seen its net margin thin to 2.5% from a three-year average of 3.2%, primarily due to underperformance in its Medicaid segment. While the company has successfully restructured its Medicare Advantage business, it is now focusing on repairing Medicaid margins, including exiting unprofitable markets. Management's 2026 adjusted earnings-per-share guidance relies on Medicare Advantage and individual ACA, and the second half of 2026 will be crucial in determining if the Medicaid margin outlook is a prudent reflection or a sign of deeper issues.

Amgen's stock (AMGN) fell sharply by 10% after Novartis' cholesterol drug Pelacarsen failed a Phase 3 trial, even though Amgen was not directly involved. Analysts believe the sell-off was overdone as Amgen's own cholesterol candidate, Olpasiran, differs significantly in potency and dosing, and its established PCSK9 drug, Repatha, continues to show strong revenue growth. Despite the market reaction, institutional investors are reportedly focusing on Amgen's strong balance sheet rather than the competitor's trial results.

A class action lawsuit has been filed against Lowe's Cos. Inc. alleging that the retailer raised prices to cover tariffs imposed by the International Emergency Economic Powers Act, then failed to reimburse shoppers after receiving $80 million in government refunds. The lawsuit claims Lowe's is unjustly enriching itself by keeping these refunds without establishing a process to repay customers who bore the initial costs through higher prices. The suit seeks to represent a nationwide class of shoppers and demands that Lowe's repay the tariff costs or distribute a proportionate share of the refunds.

Digital Realty Trust (DLR) stock is trading higher after BTIG raised its price forecast, citing accelerating demand for AI infrastructure and a growing development pipeline. BTIG noted stronger data center demand driven by hyperscaler spending and cloud growth, maintaining a Buy rating and increasing the price target to $220. The firm views DLR's recent pullback as a buying opportunity, emphasizing the strengthening fundamental backdrop for data centers.

Colgate-Palmolive (CL) stock dipped 1% after reports surfaced that the company plans to sell some of its personal care brands, including Softsoap, Irish Spring, and Speed Stick, to raise approximately $1 billion. Despite strong recent financial results, including beating EPS estimates and matching revenue expectations, CL stock has underperformed the broader market over the last five years. Wall Street analysts currently give Colgate-Palmolive a Moderate Buy rating with an average price target implying 14% upside.

Daré Bioscience is transitioning from a development-stage biotech to a commercial-stage women's health company, with two revenue-generating products launching or recently launched and a pipeline of additional products. The company emphasized its integrated commercial model through DARE Health Hub, telehealth, and digital marketing, highlighting that women's health is an underserved market with significant commercial opportunity. Daré also noted its strong cash position and success in securing over $75 million in non-dilutive funding since 2017 to advance its pipeline, including Ovaprene and DARE-HPV.

Clipper Realty (NYSE:CLPR) Director Sam Levinson purchased 6,842 shares of the company's stock for $22,168.08, increasing his total holdings to 268,304 shares. This transaction is part of a series of recent purchases by Levinson, highlighting continued insider buying. The article also notes the company's dividend yield of 11.3% and its recent downgrade by Wall Street Zen from "hold" to "sell."